1. Is Glaxosmithkline Pharmaceuticals Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Pharmaceuticals Ltd is a good quality company.
2. Is Glaxosmithkline Pharmaceuticals Ltd undervalued or overvalued?
The key valuation ratios of Glaxosmithkline Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Glaxosmithkline Pharmaceuticals Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Glaxosmithkline Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||23%||33.9%||23.1%||26.8%||18.7%||14.5%||16.9%||20.4%||10.8%||30.5%||-|
|Value Creation Index ⓘ||NA||1.5||1.1||1.4||0.7||0.3||0.5||0.8||-0.0||1.7||-|
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||9.6%||-3.1%||3.2%||5.5%||2.5%||-1.3%||8.9%||3.1%||-0.8%||-|
|Adj EPS ⓘ||26.5||39.5||27.3||24.2||22.1||18||20.3||25.2||12.4||29.7||29.3|
|YoY Gr. Rt. %||-||49.3%||-30.9%||-11.3%||-8.6%||-18.8%||13.3%||24.1%||-50.8%||139.3%||-|
|BVPS (₹) ⓘ||114.3||118.5||117.5||86.4||128.9||118.5||121.4||126.3||107.5||88.5||76.5|
|Adj Net Profit ⓘ||448||669||462||410||374||304||344||427||210||503||496|
|Cash Flow from Ops. ⓘ||335||314||281||270||139||234||473||409||491||578||-|
|Debt/CF from Ops. ⓘ||0||0||0||0||0||0||0||0||0||0||-|
CAGR ⓘCAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||1.3%||6.1%||13.5%||139.3%|
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||23.1||33.9||23.1||26.8||18.7||14.5||17||20.4||10.6||30.3||35.5|
|Op. Profit Mgn % ⓘ||31.3||29||18.5||17.1||16.9||14.4||17.9||19.4||20.8||21.7||23.2|
|Net Profit Mgn % ⓘ||18.3||24.8||17.7||15.2||13.2||10.5||12||13.7||6.5||15.7||14.3|
|Debt to Equity ⓘ||0||0||0||0||0||0||0||0||0||0||0|
|Working Cap Days ⓘ||259||97||107||95||359||573||625||601||354||143||194|
|Cash Conv. Cycle ⓘ||-8||7||8||5||19||24||12||0||9||14||62|
Return on Equity has increased versus last 3 years average to 35.50%
Net Profit is growing at healthy rate in last 3 years 13.47%
Sales growth is good in last 4 quarters at 12.91%
Sales growth has been subdued in last 3 years 3.66%
|TTM EPS (₹)||29.1||29.3|
|TTM Sales (₹ Cr.)||3,431||3,471|
|BVPS (₹.) ⓘ||77.5||76.5|
|Reserves (₹ Cr.) ⓘ||1,143||1,126|
|From the Market|
|52 Week Low / High (₹)||1379.00 / 1917.00|
|All Time Low / High (₹)||20.31 / 1925.00|
|Market Cap (₹ Cr.)||29,322|
|Equity (₹ Cr.)||169.4|
|Face Value (₹)||10|
|Industry PE ⓘ||39.8|
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.
With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products.
The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra.
Business area of the company
The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.
Award and recognition